GenoTwin Revenue and Competitors
Estimated Revenue & Valuation
- GenoTwin's estimated annual revenue is currently $1.6M per year.
- GenoTwin's estimated revenue per employee is $155,000
Employee Data
- GenoTwin has 10 Employees.
- GenoTwin grew their employee count by -9% last year.
GenoTwin's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Senior Research Scientist | Reveal Email/Phone |
3 | Data Scientist | Reveal Email/Phone |
GenoTwin Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is GenoTwin?
At GenoTwin, our core mission is to weave the power of genomics into the public health fabric by providing both powerful and practical solutions to the world's pressing infectious disease challenges. Specifically, we have developed an innovative genomics platform that combines cutting-edge capabilities in genomics, artificial intelligence, and bioinformatics to support clinicians, public health officials, and researchers. Out solutions encompass four key areas: - Pathogen detection - Pathogen surveillance - Immune/resistance assessment - Precision treatment development We were founded by leaders in this field and are supported by a Scientific Advisory Board of widely esteemed scientists and practitioners in genomics, virology, infectious disease, and epidemiology.
keywords:N/AN/A
Total Funding
10
Number of Employees
$1.6M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.8M | 10 | -17% | N/A |
#2 | $1.3M | 10 | -57% | N/A |
#3 | $0.9M | 10 | -33% | N/A |
#4 | $1.5M | 10 | -50% | N/A |
#5 | $1.1M | 10 | 43% | N/A |